药学研究2016，Vol.35Issue(7)：422-424,3.DOI:10.13506/j.cnki.jpr.2016.07.016
伊班膦酸钠对肝癌并骨转移骨钙素及骨碱性磷酸酶的影响
The effects of ibandronate on OST and BAP in hepatic carcinoma with bone metastases patients
张囡囡 1李静 1杨舒 1曹忠书1
作者信息
- 1. 山东省枣庄矿业集团中心医院，山东 枣庄 277800
- 折叠
摘要
Abstract
Objective To investigate the prognosis of OST(osteocalcin)and BAP(bone alkaline phosphatase)for he-patic carcinoma with bone metastases patients and valuation of Ibandronate. Methods 16 patients of hepatic carcinoma with bone metastases,22 patients of hepatic carcinoma without bone metastases and 20 patients of hepatic carcinoma without metastases were collected. The hepatic carcinoma with bone metastases group was treated with Ibandronate. To observe the defferences of BAP and OST in three groups and treatment or not. Results The levels of serum OST in hepatic carcinoma with bone metastases group,hepatic carcinoma without bone metastases group and hepatic carcinoma without metastases group were 31. 12 ± 4. 18,13. 00 ± 6. 92,10. 23 ± 1. 34,respectively;And the levels of BAP in three groups were 20. 11 ± 1. 65,11. 41 ± 1. 25,10. 78 ± 1. 35,respectively. The levels of OST and BAP increased significantly in the bone metastasis group(P < 0. 05). Ibandronate Injection reduced the levels of OST and BAP in hepatic carcinoma with bone metastasis group. Conclusion The value of BAP and OST were significantly higher in hepatic carcinoma with bone metastases pa-tients,which can be used as reference index of clinical prediction. Ibandronate Injection was effective in the treatment of bone metastases and the mechanism may be related to reduce the levers of OST and BAP.关键词
肝癌/骨转移/骨钙素/骨碱性磷酸酶/伊班膦酸钠Key words
Hepatic carcinoma/Bone metastasis/Osteocalcin/Bone alkaline phosphatase/Ibandronate分类
医药卫生引用本文复制引用
张囡囡,李静,杨舒,曹忠书..伊班膦酸钠对肝癌并骨转移骨钙素及骨碱性磷酸酶的影响[J].药学研究,2016,35(7):422-424,3.
